Graham, D.Y.; Naser, S.A.; Borody, T.; Hebzda, Z.; Sarles, H.; Levenson, S.; Hardi, R.; Arłukowicz, T.; Svorcan, P.; Fathi, R.;
et al. Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease. Antibiotics 2024, 13, 694.
https://doi.org/10.3390/antibiotics13080694
AMA Style
Graham DY, Naser SA, Borody T, Hebzda Z, Sarles H, Levenson S, Hardi R, Arłukowicz T, Svorcan P, Fathi R,
et al. Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease. Antibiotics. 2024; 13(8):694.
https://doi.org/10.3390/antibiotics13080694
Chicago/Turabian Style
Graham, David Y., Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi,
and et al. 2024. "Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease" Antibiotics 13, no. 8: 694.
https://doi.org/10.3390/antibiotics13080694
APA Style
Graham, D. Y., Naser, S. A., Borody, T., Hebzda, Z., Sarles, H., Levenson, S., Hardi, R., Arłukowicz, T., Svorcan, P., Fathi, R., Bibliowicz, A., Anderson, P., McLean, P., Fehrmann, C., Harris, M. S., Zhao, S., & Kalfus, I. N.
(2024). Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease. Antibiotics, 13(8), 694.
https://doi.org/10.3390/antibiotics13080694
